This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Nathan Sadeghi-Nejad

Contributor

Nathan Sadeghi-Nejad has 15 years experience as a professional health-care investor, most recently as a sector head for Highside Capital. He has worked on the sell side (with independent research boutiques Sturza¿s Medical Research and Avalon Research) and the buyside (at Kilkenny Capital prior to Highside). Sadeghi-Nejad is a graduate of Columbia University and lives in New York. You can follow him on Twitter @natesadeghi.

Nathan Sadeghi-Nejad
By This Author:
Page 2 of 5

Making The Call: Celgene's Abraxane Will Work in Pancreatic Cancer

By Nathan Sadeghi-Nejad

A key question is whether Abraxane will be used more than a cheaper, four-drug chemo cocktail.

06:00AM 10/15/12

Sarepta Shares Still Have Upside

By Nathan Sadeghi-Nejad

Contributor Nate Sadeghi works the numbers and says Sarepta is still under-valued.

10:43AM 10/03/12

Threshold's Pancreatic Cancer Drug May be Obsolete Before Launch

By Nathan Sadeghi-Nejad

Improved treatments for pancreatic cancer challenge the relevance of Threshold's TH-302

07:30AM 10/01/12

A New Reason to be Bullish About Sarepta Therapeutics

By Nathan Sadeghi-Nejad

A longer study blind suggests eteplirsen is really helping muscular dystrophy patients.

07:00AM 09/24/12

Idenix Pharma: Guilty By Association

By Nathan Sadeghi-Nejad

Idenix shares are dead money due to FDA safety concerns about Idenix's lead hepatitis C drug.

07:48AM 09/21/12

Bull Case on Peregrine Pharma Shouldn't Be Dismissed

By Nathan Sadeghi-Nejad

Believers in Peregrine's lung cancer drug bavituximab state their case.

09:33AM 09/17/12

Peregrine Pharma: Not Good Enough to Own, Too Risky to Short

By Nathan Sadeghi-Nejad

Nate Sadeghi examines Peregrine's lung cancer drug bavituximab

11:53AM 09/10/12

More Reasons to Invest in Sarepta With Caution

By Nathan Sadeghi-Nejad

Nate Sadeghi answers critics who think he's being too hard on Sarepta and its DMD drug eteplirsen.

10:35AM 08/27/12

Sarepta's Risks Shouldn't Be Ignored

By Nathan Sadeghi-Nejad

There are legit reasons to like Sarepta Therapeutics but only if these red flags can be avoided.

07:00AM 08/21/12

In These Turbulent Times, Reach for Merck

By Nathan Sadeghi-Nejad

The company's pipeline could deliver an upside surprise, plus you get a 4% dividend while you wait.

09:03AM 08/13/12

Page 2 of 5

Select the service that is right for you!

COMPARE ALL SERVICES
Action Alerts PLUS
Try it NOW

Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
  • Weekly roundups
TheStreet Quant Ratings
Try it NOW
Only $49.95/yr

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
  • Upgrade/downgrade alerts
Stocks Under $10
Try it NOW

David Peltier, uncovers low dollar stocks with extraordinary upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
  • Weekly roundups
Dividend Stock Advisor
Try it NOW

Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Alerts when market news affect the portfolio
  • Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
Real Money Pro
Try it NOW

All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.

Product Features:
  • Real Money + Doug Kass Plus 15 more Wall Street Pros
  • Intraday commentary & news
  • Ultra-actionable trading ideas
Options Profits
Try it NOW

Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • 100+ monthly options trading ideas
  • Actionable options commentary & news
  • Real-time trading community
  • Options TV
DOW 16,804.71 -238.19 -1.40%
S&P 500 1,946.16 -26.13 -1.32%
NASDAQ 4,422.0850 -71.3050 -1.59%

Brokerage Partners

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs